Revision | Oct. 24, 2024 | Texas DUR Board approved criteria: - Anti-diabetic Agents (oral)
- Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder Medications
- Glucagon-like Peptide 1 Receptor Agonists
- Pramlintide
- Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting (oral)
- Substance P/Neurokinin 1 Receptor Antagonists
|
Revision | July 26, 2024 | Texas DUR Board approved criteria: - Fluoroquinolones (oral)
- Hepatitis C direct-acting antivirals
- Immune globulins
- Non-sedating antihistamines
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Rifaximin (Xifaxan)
- Sickle cell disease products
- Skeletal muscle relaxants
|
Revision | July 1, 2024 | Revised Drug Use Compendia published |
Revision | April 26, 2024 | Texas DUR Board approved criteria: - Benzodiazepines (oral, nasal, rectal)
- Complement inhibitor and enzyme/ protein replacement therapy
- Direct oral anticoagulants
- Hydroxy-methylglutaryl coenzyme-A reductase inhibitors (statins)
- Low molecular weight heparins
- Nebulized bronchodilators
|
Revision | Jan. 26, 2024 | Texas DUR Board approved criteria: - Fentanyl
- Gabapentin
- Hydrocodone Bitartrate/ Hydrocodone Polistirex
- Ivacaftor (Kalydeco) and Lumacaftor/Ivacaftor (Orkambi)
- Topical Calcineurin Inhibitors
- Tramadol
|
Revision | Oct. 13, 2023 | Texas DUR Board approved criteria: - Atypical Antipsychotics (long-Acting Injectable)
- Atypical Antipsychotics (oral)
- Exogenous Insulin Products
- Nitazoxanide (Alinia)
- Promethazine Use in Children Less than 2 Years of Age
- Quetiapine (low dose)
|
Revision | July 21, 2023 | Texas DUR Board approved criteria: - Acetylcholinesterase Inhibitors
- Cyclooxygenase-2 Inhibitors
- Histamine H2- Receptor Antagonists
- Ketorolac (oral)
- Leukotriene Receptor Antagonists
- Mecasermin
- Memantine
|
Revision | April 28, 2023 | Texas DUR Board approved criteria: - Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Cholinergic Drugs
- Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Inflammatory Drugs
- Aerosolized Agents - Metered-Dose Inhalers (MDIs): Beta2 Adrenergic Drugs (long-acting)
- Aerosolized Agents - Metered-Dose Inhalers (MDIs): Beta2 Adrenergic Drugs (short-acting)
- Anti-Depressants, Oral (other)
- Anti-Depressants, Selective Serotonin Reuptake Inhibitors
|
Revision | Jan. 20, 2023 | Texas DUR Board approved criteria: - Angiotensin II Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Proton Pump Inhibitors
- Sedative/Hypnotics
- Serotonin 5-HT1B/1D Receptor Agonists
|
Revision | Oct. 21, 2022 | Texas DUR Board approved criteria: - Anti-Diabetic Agents (oral)
- Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder Medications
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
- Pramlintide
- Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting (oral)
- Substance P/Neurokinin1 Receptor Antagonists
|
Baseline | Oct. 20, 2021 | Initial publication of content as the VDP Retrospective Drug Use Criteria Handbook. |